Free Trial

MetLife (MET) Stock Forecast & Price Target

MetLife logo
$100.73 +0.46 (+0.46%)
Closing price 10/16/2026 03:59 PM Eastern
Extended Trading
$100.52 -0.21 (-0.21%)
As of 10/16/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

MetLife - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Sell
0
Hold
2
Buy
13

Based on 15 Wall Street analysts who have issued ratings for MetLife in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 15 analysts, 2 have given a hold rating, and 13 have given a buy rating for MET.

Consensus Price Target

$105.19
4.42% Upside
According to the 15 analysts' twelve-month price targets for MetLife, the average price target is $105.19. The highest price target for MET is $115.00, while the lowest price target for MET is $80.00. The average price target represents a forecasted upside of 4.42% from the current price of $100.73.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for MET and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for MetLife and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

MET Analyst Ratings Over Time

TypeCurrent Forecast
10/17/25 to 10/17/26
1 Month Ago
9/17/25 to 9/17/26
3 Months Ago
7/19/25 to 7/19/26
1 Year Ago
10/17/24 to 10/17/25
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
13 Buy rating(s)
13 Buy rating(s)
12 Buy rating(s)
9 Buy rating(s)
Hold
2 Hold rating(s)
2 Hold rating(s)
3 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$105.19$103.06$97.20$95.18
Forecasted Upside4.42% Upside5.87% Upside3.42% Upside21.17% Upside
Consensus RatingModerate BuyModerate BuyModerate BuyModerate Buy

MET Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

MET Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

MetLife Stock vs. The Competition

TypeMetLifeFinance CompaniesBroader Market
Consensus Rating Score
2.87
2.28
2.53
Consensus RatingModerate BuyHoldModerate Buy
Predicted Upside4.42% Upside39.55% Upside18.02% Upside
News Sentiment Rating
Positive News

See Recent MET News
Positive News
Positive News
Report Date
0 Results
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
10/15/2026
Pablo Singzon
Pablo Singzon
Not Rated
Boost TargetOverweight$108.00 ➝ $110.00+11.30%
10/12/2026Boost TargetOverweight$109.00 ➝ $110.00+10.59%
10/7/2026
Mizuho logo
Mizuho
3 of 5 stars
Yaron Kinar
Yaron Kinar
Not Rated
Lower TargetOutperform$112.00 ➝ $109.00+13.45%
10/7/2026Boost TargetOverweight$97.00 ➝ $111.00+14.17%
10/6/2026Boost TargetBuy$105.00 ➝ $110.00+13.44%
10/5/2026Boost TargetBuy$105.00 ➝ $110.00+14.29%
9/22/2026UpgradeNeutral ➝ Overweight$99.00 ➝ $110.00+13.71%
9/11/2026 Reiterated RatingBuy (B)
9/2/2026 Boost TargetBuy$93.00 ➝ $109.00+9.16%
8/24/2026 Reiterated RatingMixed
8/24/2026Boost TargetOverweight$103.00 ➝ $111.00+16.15%
8/11/2026Boost TargetOutperform$105.00 ➝ $108.00+11.39%
8/10/2026Boost TargetBuy$103.00 ➝ $115.00+15.17%
7/15/2026 Set Target$103.00+11.65%
7/15/2026Lower TargetBuy$106.00 ➝ $103.00+3.15%
5/15/2026 Boost TargetMarket Perform$78.00 ➝ $80.00-19.88%
2/6/2026 Lower TargetOutperform$91.00 ➝ $89.00-10.87%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 11:01 PM ET.


Should I Buy MetLife Stock? MET Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, October 15, 2026. Please send any questions or comments about these MetLife pros and cons to contact@marketbeat.com.

MetLife
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in MetLife, Inc.:

  • MetLife, Inc. recently hit a new 52-week high of $101.44, with the current stock price trading at $100.27, reflecting strong momentum and market confidence in the company's recent performance and strategic direction.
  • Analyst sentiment has turned increasingly positive, with JPMorgan Chase & Co. raising its price target to $110.00 and DOWLING & PARTN lifting its FY2026 earnings estimate to $10.30 per share, which is significantly above the consensus estimate of $9.88, suggesting potential for higher-than-expected profitability.
  • The company demonstrated strong earnings power in its most recent quarterly report, beating consensus estimates by $0.13 per share with an EPS of $2.43, while maintaining a robust return on equity of 23.39%, indicating efficient use of shareholder capital.
  • MetLife, Inc. has approved a $3.00 billion stock repurchase plan, which allows the company to buy back up to 4.8% of its shares, a move that often signals management believes the stock is undervalued and can support share price growth by reducing the number of outstanding shares.
  • With a dividend yield of 2.37% and a beta of 0.78, the stock offers a relatively stable income stream with lower volatility compared to the broader market, making it an attractive option for income-focused investors seeking defensive exposure.

MetLife
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in MetLife, Inc. for these reasons:

  • Despite beating earnings estimates, MetLife, Inc. reported revenue of $13.52 billion in its latest quarter, which fell significantly short of the consensus estimate of $19.67 billion, raising concerns about the sustainability of its top-line growth and revenue generation capabilities.
  • The company's current ratio and quick ratio are both at 0.20, indicating that it has significantly more current liabilities than current assets, which could pose liquidity challenges in the event of unexpected financial pressures or market downturns.
  • MetLife, Inc. carries a debt-to-equity ratio of 0.52, meaning it relies on a moderate level of debt to finance its operations, which could increase financial risk if interest rates rise or if the company's earnings decline, potentially impacting its ability to service debt.
  • While the stock has risen to new highs, it is trading near its 52-week high of $101.44, which may limit near-term upside potential and increase the risk of a pullback if market sentiment shifts or if the company fails to meet elevated analyst expectations.
  • The company's revenue growth of 10.5% year-over-year, while positive, may not be sufficient to offset the significant gap between actual and consensus revenue estimates, suggesting that the market's expectations for revenue growth may be overly optimistic and could lead to disappointment in future quarters.

MET Forecast - Frequently Asked Questions

According to the research reports of 15 Wall Street equities research analysts, the average twelve-month stock price forecast for MetLife is $105.19, with a high forecast of $115.00 and a low forecast of $80.00.

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MetLife in the last twelve months. There are currently 2 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" MET shares.

According to analysts, MetLife's stock has a predicted upside of 4.42% based on their 12-month stock forecasts.

Over the previous 90 days, MetLife's stock had 1 upgrade by analysts.

Analysts like MetLife more than other "finance" companies. The consensus rating for MetLife is Moderate Buy while the average consensus rating for "finance" companies is Hold. Learn more on how MET compares to other companies.


MarketBeat monitors more than a dozen sources for MetLife analyst ratings, with the most recent rating issued on 10/15/2026.
From Our Partners